The Complete Media Intelligence Report on Leading Pharma Companies
Comprehensive analysis of social media and mainstream media coverage of Pfizer, Merck & Co., Johnson & Johnson, and 7 other pharmaceutical giants shaping healthcare’s future.
What’s in the report?
- 12-Month Data Analysis | November 2024 to October 2025 insights
- Share of Voice Analysis | Which pharma companies dominate social and mainstream media conversations
- Hashtag Performance | Top-performing social media campaigns and patient movements
- LinkedIn Landscape | What pharma companies post vs. what professionals and users discuss about them
- Media vs Social Comparison | What journalists cover vs. what consumers actually discuss
- Challenge Landscape | The 15 critical obstacles facing pharmaceutical companies in 2026
- AI Pipeline Revolution | How artificial intelligence is transforming drug discovery and development
- Trump Policy Impact | TrumpRx, tariffs, and pricing reforms reshaping the industry
- Genomic Therapies Deep Dive | CRISPR, CAR-T, and mRNA developments beyond COVID-19
- Vaccine Trust Analysis | Measuring declining confidence and policy shifts impacting immunization
Key Findings
- Pfizer dominates social media with 10.4M mentions vs. 1.01M in mainstream media
- COVID vaccines aftermath drives 16.85% of social conversations – the industry’s most discussed topic
- Supply chain diversification tops 2026 challenges at 25.1% amid geopolitical risks
- Innovation & R&D accounts for 50.30% of pharma companies’ LinkedIn content vs. 28.3% focused on drug pricing in earned discussions
- AstraZeneca leads AI pipeline discussions at 16.1%, outpacing Pfizer and Eli Lilly
- Only 0.11% of drug conversations link medications to their manufacturers – fragmented brand awareness
- Childhood vaccination debates dominate 42% of vaccine discussions following policy shifts
- Regulatory & Safety Support leads AI applications at 34.3% of pharma AI conversations
- Pfizer captures 50.56% of discussions around Trump’s pharmaceutical policies
- FDA approvals account for 33.9% of mainstream media coverage vs. mixed social sentiment
- Eli Lilly’s Mounjaro generates high engagement in GLP-1 weight-loss category